Skip to main
CELU
CELU logo

Celularity (CELU) Stock Forecast & Price Target

Celularity (CELU) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Celularity Inc. is positioned favorably in the biotechnology sector due to its innovative offerings in placental-derived cell therapies, with a current revenue stream predominantly from the bio-banking segment. The company's clinical results, notably the PDA-002, have demonstrated significant ulcer closure rates of 42.8% and 53.8% at 12 and 20 weeks, respectively, which compare positively against established FDA-approved products such as Dermagraft and Dermapace. Furthermore, the enhanced wound healing durability exhibited by PDA-002 underscores the potential for competitive advantage within the regenerative medicine market.

Bears say

Celularity Inc faces significant risks associated with manufacturing failures that could adversely impact its clinical trials, potentially hampering its biobanking and degenerative diseases segments, which are crucial for generating revenue. Furthermore, the declining function of NK cells with age, characterized by reduced cytokine secretion and decreased target cell cytotoxicity, poses a hurdle in effectively utilizing its cell therapy innovations. This combined uncertainty surrounding operational execution and biological efficacy contributes to a negative outlook on the company's stock performance.

Celularity (CELU) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Celularity and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Celularity (CELU) Forecast

Analysts have given Celularity (CELU) a Strong Buy based on their latest research and market trends.

According to 1 analysts, Celularity (CELU) has a Strong Buy consensus rating as of Dec 15, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Celularity (CELU)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.